Preclinical News and Research

RSS

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

A new study, published in Nano Letters, describes an effective new COVID-19 vaccine candidate based on a messenger ribonucleic acid (mRNA) platform.

28 May 2021

Scientists investigate sex-targeted drug delivery for traumatic brain injuries

New research has determined that the window of opportunity to provide possible treatments for patients suffering from traumatic brain injuries (TBIs) differs depending on whether the patient is male or female.

28 May 2021

Corning launches HepGo Assay-ready 3D liver spheroid kit

Corning Incorporated today announced the launch of its HepGo™ Assay-ready 3D liver spheroid kit, the first plug-and-play solution to include 96 pre-plated primary human hepatocyte (PHH) spheroids in a single-spheroid microplate (one uniform spheroid per well) and HepGo Hepatocyte companion cell culture media.

28 May 2021

Melatonin prevents kidney damage caused by metabolic complications of obesity

Scientists from the University of Granada (UGR), the Hospital Universitario La Paz (Madrid), and the University of Texas (USA) have taken an important step in the fight against kidney damage and its progression towards kidney failure, which is closely related to diabesity (obesity and its type 2 diabetes) and its complications.

27 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

STING agonist diABZI shows promise against SARS-CoV-2 variants

COVID-19 vaccines are the most effective way to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. For people who are already infected, new research suggests the small molecule stimulator of interferon genes (STING) agonist-1, diABZI, may be effective in controlling SARS-CoV-2 infection — including those caused by variants.

23 May 2021

Asthma patients can benefit from type 2 diabetes medication

Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

21 May 2021

Researchers define immune determinants of protection against SARS-CoV-2 in mice

Researchers in the United States have conducted a preclinical study defining the roles that different arms of the immune system play in fighting primary infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as reinfection and infection following SARS-CoV-2 vaccination.

21 May 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

New peptides allow cannabis-derived drugs to fight pain in mice without side effects

An international team, led by researchers from Pompeu Fabra University (UPF) in Barcelona, Spain, David Andreu and Rafael Maldonado, has developed a peptides family that allows delta-9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, to fight pain in mice without side effects.

20 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Researchers report promising biotherapeutics for obesity and related medical complications

The research teams at the University of Hong Kong led by Professor Xuechen LI from the Research Division for Chemistry and Department of Chemistry, and Professor Yu WANG from the Department of Pharmacology and Pharmacy, reported a synthetic biotherapeutics with promising anti-tumor, insulin sensitising and hepatoprotective activities in the Journal of the American Chemical Society.

18 May 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

17 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

Preclinical News and Research

New LNP-based mRNA vaccine candidate protects against lethal SARS-CoV-2 in preclinical trials

Scientists investigate sex-targeted drug delivery for traumatic brain injuries

Corning launches HepGo Assay-ready 3D liver spheroid kit

Melatonin prevents kidney damage caused by metabolic complications of obesity

Could GRP78 be a therapeutic target against COVID-19?

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

STING agonist diABZI shows promise against SARS-CoV-2 variants

Asthma patients can benefit from type 2 diabetes medication

Researchers define immune determinants of protection against SARS-CoV-2 in mice

Intranasal COVID-19 therapeutic shows promise in preclinical trials

New peptides allow cannabis-derived drugs to fight pain in mice without side effects

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Researchers report promising biotherapeutics for obesity and related medical complications

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Pirfenidone significantly reduces a marker of heart muscle scarring

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics